Botanical species · safety record

Drimia maritima

The EFSA Compendium of Botanicals holds 3 constituent measurements and 4 adverse-effect records for Drimia maritima. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Drimia maritima (L.) Stearn

3Constituent measurements

4Safety records

6Cited sources

3Licensed products (Canada)

Also recorded as

Urginea maritima (L.) Baker
Scilla maritima L.

Synonyms are carried from the source compendium. A species may be traded and studied under more than one name, which is exactly how a safety record gets lost.

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 3 licensed products naming Drimia maritima as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Source material stated

Bulb

What the records describe

Constituents measured

Plant parts

Preparations

Effect types

Target tissues

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Proscillaridin a	Live plants	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Proscillaridin a	Bulb / clove	Solvent extraction	—	—	No resolvable identifier
Scillaren a	Bulb / clove	Solvent extraction	—	—	No resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

Effect	Target tissue	Plant part	Preparation	Test organism	Test type	Source
Systemic	—	Bulb / clove	Powder	Rat (as animal)	Acute toxicity	Resolve DOI
Systemic	—	Bulb / clove	Powder	Rat (as animal)	Acute toxicity	Resolve DOI
Digestive	—	Bulb / clove	Powder	Pig (as animal)	Case report	No resolvable identifier
Systemic	Cardiovascular / haematological	Bulb / clove	—	Human (as organism)	Case report	No resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Gwatkin, R., Plummer, P J. Toxicity of Red Squill for Swine and Rats.. Canadian journal of comparative medicine and veterinary science, 1943, vol. 7, no. 8, p. 244-9.
TUNCOK, Y., KOZAN, O., CAVDAR, C., GUVEN, H., FOWLER, J. URGINEA MARITIMA (SQUILL) TOXICITY. Journal of toxicology-clinical toxicology, 1995, vol. 33, no. 1, p. 83-86.
Garcia Casado, P., Renedo, M. J., Fernandez, M., Vega, F. A. Proscillaridin A yield from Squill bulbs. Pharmaceutica acta helvetiae, 1977, vol. 52, no. 9, p. 218-21.
El-Seedi, Hesham R., Burman, Robert., Mansour, Ahmed., Turki, Zaki., Boulos, Loutfy., Gullbo, Joachim., Goransson, Ulf. The traditional medical uses and cytotoxic activities of sixty-one Egyptian plants: Discovery of an active cardiac glycoside from Urginea maritima . Journal of ethnopharmacology, 2013, vol. 145, no. 3, p. 746-757. DOI
O'connor, M.G., Buck, R.E., Fellers, C.R. Red Squill Investigations Properties, Toxicity, and Palatability of Red Squill and Powder Baits to Rats. Industrial and engineering chemistry, 1935, vol. 27, no. 11, p. 1377-1380. DOI
Radomski, Jack L., Woodard, Geoffrey. Present status of red squill as a rodenticide. Journal of the american pharmaceutical association, scientific edition, 1946, vol. 35, p. 289-95.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature